• 1
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 15011506.
  • 2
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 15061510.
  • 3
    Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192199.
  • 4
    Patterson J, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990; 12: 11321146.
  • 5
    Ning Q, Brown D, Parodo J, Cattral M, Fung L, Liu M, Rotstein O, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Thl cytokine production, but inhibits Th2 cytokine response [Abstract]. Hepatology 1996; 24: 355A.
  • 6
    Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 10581061.
  • 7
    Reichard O, Yun Z-B, Sönnerborg A, Weiland O. Hepatitis C viral RNA liters in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99102.
  • 8
    Di Bisceglie A, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, et al. Pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649654.
  • 9
    Camps J, Garcia N, Rieza-Boj J, Civiera M, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993; 19: 408412.
  • 10
    Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591598.
  • 11
    Bodenheimer H, Lindsay KL, Davis GL, Lewis JH, Thung SN, Mahaney K, Seeff L. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial [Abstract]. Hepatology 1994; 20: 207A.
  • 12
    Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdayin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897903.
  • 13
    Di Bisceglie A, Bacon B, Kleiner D, Hoofnagle J. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994; 21: 11091112.
  • 14
    Brillianti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterol-ogy 1994; 107: 812817.
  • 15
    Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23 (suppl 2): 1721.
  • 16
    Brouwer J, Nevens F, Michielsen P, Hautekeetem L, Chamuleau RAFM, Adler M, Delwaide J, et al. What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon [Abstract]. Hepatol 1994; 21: 17A.
  • 17
    Pol S, Berthelot P, Bechot C. Ribavirin-interferon vs interferon (alfa 2b-IFN) alone in non-responders to alpha-IFN in chronic hepatitis C [Abstract]. Hepatology 1996; 24: 356A.
  • 18
    Schalm S, Hansen B, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Calvalletto L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: a meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961966.
  • 19
    Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 (suppl 2): 812.
  • 20
    Braconier J, Paulsen O, Engman K, Widell A. Combined alpha-inter-feron and ribavirin treatment for chronic hepatitis C virus infection. Scand J Infect Dis 1995; 27: 325329.
  • 21
    Kakumu S, Yoshioko K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507512.
  • 22
    Lai M-Y, Kao J-H, Yang P-M, Wang JT, Chen PJ, Chan KW, Chu JS, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 13071312.
  • 23
    Reichard O, Glaumann H, Fryden A, Norkrans G, Schwarcz R, Sonnerborg A, Yun Z-B, et al. Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918922.
  • 24
    Reichard O, Norkrans G, Fryden A, Braconier J-H, Alaeus A, Glaumann H, Schwarcz R, et al. Alfa-interferon and ribavirin versus alfa-interferon alone as therapy for chronic hepatitis C-a randomized, double-blind, placebo-controlled study [Abstract]. Hepatology 1996; 24: 356A.
  • 25
    Bizzolon T, Palazzo U, Chevallier M, Dicerf C, Trepo C. HCV recurrence after OLT: a pilot study of ribavirin therapy following initial combination with IFN [Abstract]. Hepatology 1996; 24: 293A.
  • 26
    Dodson S, Araya V, Lee R, Rossaro L, Rakela J, Fung J. Preliminary analysis of combination alpha-interferon/ribavirin therapy for recurrent hepatitis C following liver transplantation [Abstract]. Hepatology 1996; 24: 295A.
  • 27
    Gane E, Lo S, Portman B, Lau J, Naoumov N, Williams R. A randomised study of the safety and efficacy of ribavirin vs. interferon monotherapy for recurrent HCV infection in liver transplant recipients [Abstract]. Hepatology 1996; 24: 293A.
  • 28
    Ljungman P, Andersson J, Aschan J, Björkstrand B, Hagglund H, Lönn-qvist B, Ringdén O, et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogenic bone marrow transplantation. Clin Infect Dis 1996; 23: 167169.
  • 29
    Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepatitis 1996; 3: 247252.